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Introduction
Systemic juvenile idiopathic arthritis (SJIA) is regarded as
an autoinflammatory disease (AID) of unknown etiology
related to abnormalities of the innate immune system. A
major role in the pathogenesis has been ascribed to
proinflammatory cytokines as interleukin (IL)-6 and IL-1.
Objectives
Analysis of treatment results with the IL-6 inhibitor
tocilizumab
Patients and methods
From 7/2009 to 4/2014 200 patients with SJIA were
documented in the AID-registry. 46 of 200 patients
(19 m, 27 f) at the age of 1-18 years (median 9) received
therapy with tocilizumab (median 13 months, range
1-48). 24 of 46 patients received long term treatment
(median 23 months, range 12-48) and were evaluated
concerning Wallace criteria [1]. Different clinical courses
were continuous (C) n=12, polycyclic (PC) n=16, arthritic
(A) n=18. Besides we estimated a response rate (defini-
tion: no clinical manifestation and no inflammation para-
meters) in the first 12 weeks of treatment. Data are based
on the AID-Registry (http://www.aid-register.de).
Results
According to Kaplan-Meier analysis 30% reached inac-
tive disease or remission after the first 12 weeks of treat-
ment. A rapid response to tocilizumab seems to be
related to long term inactivity of SJIA. Comparison of
the three disease courses (PC, C, A) revealed significant
differences in the outcome; polycyclic courses show the
fastest response followed by continuous courses. Worst
outcome was evaluated in arthritic courses. Wallace cri-
teria measured after at least 12 months: remission 54%,
active disease 25%, inactive disease 21%. 4 (9%) patients
were non-responders over the whole time. 60% of the
patients showed no measurable CRP within the first
4 weeks and during tocilizumab therapy. Adverse events
were reported in 11 (24%) patients: most leukopenia,
infections and elevated transaminases, one Hodgkin’s
lymphoma, one gut perforation.
Conclusion
A significant proportion of patients documented with
SJIA in der German AID-registry is treated with tocili-
zumab (23%). We estimated a good response in the first
12 weeks of therapy of 30% and also by Wallace of 76%
(inactive disease or remission). The response appears to
depend on different disease phenotypes.
1The AID-Registry is funded by the BMBF (01GM08104,
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